LitAlert ~~ GeneLit.com

    • Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for Prostate Cancer Treatment.
    • Ruigrok EAM, Verkaik NS, de Blois E, de Ridder C, Stuurman D, Roobol SJ, Van Gent DC, de Jong M, Van Weerden WM, Nonnekens J.
    • Int J Mol Sci. 2022 Jul 21;23(14):8037. doi: 10.3390/ijms23148037.
    • PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib.
    • Ding X, Zhu Z, Lapek J, McMillan EA, Zhang A, Chung CY, Dubbury S, Lapira J, Firdaus S, Kang X, Gao J, Oyer J, Chionis J, Rollins RA, Li L, Niessen S, Bagrodia S, Zhang L, VanArsdale T.
    • Sci Rep. 2022 Jul 21;12(1):12501. doi: 10.1038/s41598-022-16623-3.